A disturbing botulism outbreak among infants has forced the recall of a specific brand of infant formula. As of Saturday, the Centers for Disease Control and Prevention (CDC) reported 13 cases of this illness across ten states, including Arizona, California, and Texas. These cases include babies just 16 days old to those 167 days old. The outbreak has raised serious concerns about infant safety, as all affected infants were hospitalized, though thankfully, there have been no fatalities.
The implicated product is ByHeart Whole Nutrition infant formula. On Sunday, following the CDC’s announcement, the Food and Drug Administration (FDA) mandated a recall of two batches of this formula. The FDA is currently investigating a total of 83 infant botulism cases that have emerged since August. While the FDA has yet to establish a direct connection between these reported cases and the ByHeart brand, it appears the common thread lies in these specific batches.
“While no testing by ByHeart or regulatory agencies has confirmed the presence of Clostridium botulinum spores or toxin in any ByHeart product, we are taking this proactive step to remove any potential risk from the market,” said Mia Funt, Co-Founder and President of ByHeart. This preemptive measure underscores the company’s commitment to ensuring the safety of its product, as the FDA emphasized that botulism is exceedingly rare in dairy products or infant formula. Typically, this dangerous bacteria is found in environmental sources like soil and specific vegetables.
The recall includes batches with the codes 251261P2 and 251131P2, both with a use-by date of December 1, 2026. Consumers who may have purchased these specific lots are urged to stop using the product and dispose of it. ByHeart has offered to replace any discarded formula from these batches at no charge.
Symptoms of infant botulism can be alarming, starting with constipation, poor feeding, loss of head control, and difficulty swallowing. If not addressed, these symptoms can escalate to severe issues such as respiratory arrest. Therefore, it’s crucial for parents and caregivers to remain vigilant and seek medical attention if any signs appear.
The FDA’s statement conveys seriousness regarding infant health: “Infants with botulism will initially develop constipation, poor feeding, loss of head control, and difficulty swallowing.” Timely reporting and action in this case are vital in protecting infants from the risks associated with botulism. As investigations continue, the safety of children depends on the swift management of this situation by both the manufacturer and regulatory agencies.
"*" indicates required fields
